Bionano Genomics, Inc. (BNGO) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US09075F4046
Bionano Genomics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 28.51 m USD |
| Gross profit | 13.19 m USD |
| Operating income | -33.34 m USD |
| EBIT | -27.33 m USD |
| Net income | -26.40 m USD |
| Diluted EPS – continuing operations | -4.85 USD |
Full history since 2016, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Bionano Genomics, Inc.
Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It also provides Saphyr and Stratys systems, which are sample-to-result solutions for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr and Stratys instruments, which are single-molecule imagers; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA; and Ionic purification system, which isolates and purifies nucleic acid molecules. In addition, the company offers Saphyr, Stratys, and Bionano compute servers; and VIA software, which offers one solution for solutions for cytogenetics and molecular genetics. Further, it provides testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
More stocks
- Seres Therapeutics, Inc. (MCRB)
- DarioHealth Corp. (DRIO)
- Norris Industries, Inc. (NRIS)
- Galenfeha, Inc. (NGHI)
- PACIFIC HEALTH CARE ORGANIZATION INC (PFHO)
- Hepion Pharmaceuticals, Inc. (HEPA)
- SunPower Inc. (SPWR)
- KYNTRA BIO, INC. (KYNB)
- Inhibitor Therapeutics, Inc. (INTI)
- Neuphoria Therapeutics Inc. (NEUP)
- KEEMO Fashion Group Ltd (KMFG)
- MDxHealth SA (MDXH)
Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.